Summary
Abbott Laboratories reported a solid second quarter and first six months of 2011, demonstrating robust top-line growth driven by its key segments, particularly Proprietary Pharmaceuticals and Established Pharmaceuticals. Net sales increased by 9.0% in the quarter and 12.9% year-to-date, reflecting strong performance both in the U.S. and internationally, with international sales showing particularly strong growth due to favorable exchange rates and recent acquisitions. Profitability saw a significant boost in the second quarter due to a substantial tax benefit from the favorable resolution of prior tax positions, resulting in a sharp increase in net earnings compared to the prior year. Research and development expenses increased, driven by pipeline investment and acquisitions, while selling, general, and administrative expenses showed moderate growth. The company's financial position remains strong, with substantial cash flow from operations and ample liquidity, supported by credit facilities. Management expressed confidence in the company's ongoing performance and strategic initiatives.
Financial Highlights
54 data points| Revenue | $9.62B |
| Cost of Revenue | $3.87B |
| Gross Profit | $5.75B |
| SG&A Expenses | $2.76B |
| Operating Expenses | $7.84B |
| Operating Income | $1.77B |
| Interest Expense | $134.13M |
| Net Income | $1.94B |
| EPS (Basic) | $1.24 |
| EPS (Diluted) | $1.23 |
| Shares Outstanding (Basic) | 1.56B |
| Shares Outstanding (Diluted) | 1.57B |
Key Highlights
- 1Net sales increased by 9.0% to $9.6 billion for the three months ended June 30, 2011, and by 12.9% to $18.7 billion for the six months ended June 30, 2011, compared to the prior year periods.
- 2Operating earnings for the three months ended June 30, 2011, increased by 10.4% to $1.77 billion, though operating earnings for the six-month period were relatively flat at $3.07 billion.
- 3Net earnings saw a significant increase of 50.4% to $1.94 billion for the three months ended June 30, 2011, primarily driven by a $519 million tax benefit from the resolution of prior tax positions.
- 4Diluted earnings per share rose to $1.23 for the three months ended June 30, 2011, and $1.79 for the six months ended June 30, 2011.
- 5The Proprietary Pharmaceutical Products segment and Established Pharmaceutical Products segment showed strong sales growth of 13.0% and 10.3% respectively in the quarter, and 12.4% and 36.4% respectively year-to-date.
- 6Cash flow from operations remained strong, totaling $4.5 billion for the first six months of 2011.
- 7Abbott recognized a significant tax benefit of $519 million in the second quarter of 2011 due to the favorable resolution of various tax positions pertaining to prior years.